All Stories

  1. When a Budget‐Friendly Drug Leads to a Premium Diagnosis: A Case Report of Severe Cholestasis Following Amoxicillin–Clavulanate Use

    Article • Case Reports in Hepatology, January 2025, Wiley

    Maureen Okafor

  2. Technology literacy and access to digital resources for remote assessment among adults enrolled in Alzheimer's disease research

    Article • Journal of Alzheimer’s Disease, December 2024, SAGE Publications

    Maureen Okafor

  3. Contribution of Peripheral Microvascular Dysfunction to Mild Cognitive Impairment

    Article • The American Journal of Cardiology, March 2024, Elsevier

    Maureen Okafor

  4. Subjective cognitive complaints in White and African American older adults: associations with demographic, mood, cognitive, and neuroimaging features

    Article • Aging Neuropsychology and Cognition, August 2023, Taylor & Francis

    Maureen Okafor

  5. Effects of candesartan on cerebral microvascular function in mild cognitive impairment: Results of two clinical trials

    Article • International Journal of Stroke, January 2023, SAGE Publications

    Maureen Okafor

  6. Development of digital voice biomarkers and associations with cognition, cerebrospinal biomarkers, and neural representation in early Alzheimer's disease

    Article • Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring, January 2023, Wiley

    Maureen Okafor

  7. Association of Cerebrovascular Reactivity and Cognitive Performance in a Racially Diverse Cohort

    Article • Alzheimer s & Dementia, December 2022, Wiley

    Maureen Okafor

  8. Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer’s disease

    Article • Brain Communications, October 2022, Oxford University Press (OUP)

    Maureen Okafor

  9. Association of Plasma and Cerebrospinal Fluid Alzheimer Disease Biomarkers With Race and the Role of Genetic Ancestry, Vascular Comorbidities, and Neighborhood Factors

    Article • JAMA Network Open, October 2022, American Medical Association (AMA)

    Maureen Okafor

  10. Candesartan is associated with lower amyloid accumulation in non‐hypertensive prodromal Alzheimer’s disease

    Article • Alzheimer s & Dementia, December 2021, Wiley

    Maureen Okafor

  11. Perceived stress increases Alzheimer's disease risk in African Americans

    Article • Journal of Alzheimer’s Disease, September 2020, IOS Press

    Maureen Okafor, Antoine Trammell

  12. Effects of Candesartan vs Lisinopril on Neurocognitive Function in Older Adults With Executive Mild Cognitive Impairment

    Article • JAMA Network Open, August 2020, American Medical Association (AMA)

    Maureen Okafor

  13. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer’s Disease

    Article • Journal of Alzheimer’s Disease, March 2020, IOS Press

    Maureen Okafor

  14. Modeling Cerebral Hemodynamics Using BOLD Magnetic Resonance Imaging and its Application in Mild Cognitive Impairment

    Article • February 2020, Cold Spring Harbor Laboratory Press

    Maureen Okafor

  15. P4-293: COMPARISON OF FLORTAUCIPIR PET WITH CEREBROSPINAL FLUID, COGNITIVE FUNCTIONING AND NEUROIMAGING MEASURES IN MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE

    Article • Alzheimer s & Dementia, July 2019, Wiley

    Maureen Okafor

  16. Design Elements and Enrollment Patterns of Contemporary Trials in Heart Failure With Preserved Ejection Fraction

    Article • JACC Heart Failure, August 2018, Elsevier

    Maureen Okafor

  17. Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment

    Article • Current Heart Failure Reports, January 2018, Springer Science + Business Media

    Maureen Okafor

  18. Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years

    Article • European Journal of Heart Failure, January 2018, Wiley

    Maureen Okafor